Joseph L Ruegemer, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 235 E State St, Saint Croix Falls, WI 54024 Phone: 715-483-3221 Fax: 715-483-0507 |
News Archive
The chairs of the Consultative Expert Working Group on Research and Development (CEWG), John-Arne Rottingen and Claudia Chamas, in this week's PLoS Medicine, "recommended the May 2012 World Health Assembly adopt an international convention on research and development (R&D) that will bind member states to action and catalyze new knowledge for diseases that primarily affect the global poor but for which patents provide insufficient market incentives," a PLoS press release states.
Aradigm Corporation today announced that it has received proceeds of approximately $891,000 from the exercise of all of the warrants to purchase an aggregate of 7,527,214 shares of the Company's common stock that were issued in the private placement that closed on June 21, 2010.
Zachary Mainen, coordinator of the Champalimaud Foundation Neuroscience Programme at the IGC, has become one of the most recent winners of the prestigious and highly competitive European Research Council grants, to the value of 2.3 million euro, for a period of five years.
"The latest calculations show that U.S. ethanol policies have increased the food bills of poor food-importing countries by more than $9 billion (£5.6 billion) since 2006," Olivier De Schutter, U.N. special rapporteur on the right to food, writes in the Guardian's "Poverty Matters" blog.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
› Verified 5 days ago